Ketogenic Diet for Patients With Recurrent Glioblastoma
Increased glycolysis and reduced oxidative phosphorylation is a characteristic property of
many tumors. A change of nutrition by limiting carbohydrates and increasing the proportion
of fatty acids and proteins can lead to ketogenic metabolism and might limit energy
production in tumor cells and therefore inhibit tumor growth. Standard treatment for
glioblastoma includes resection, irradiation and temozolomide chemotherapy. If there is
tumor recurrence, no standard therapy is established. Therapeutic options in this situation
include resection, irradiation or another chemotherapy. However, some patients cannot be
treated in this situation, because none of the available treatment options seems reasonable
or applicable, for example if no additional chemotherapy can be started at the time of
recurrence due to myelosuppression. The pilot study examines whether in this situation a
ketogenic diet can be applied to the patients and may inhibit tumor growth and influence the
quality of life of the patients.
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
applicability as measured by discontinuation of study treatment due to intolerability and percentage of patients in which ketosis is detectable
until progression for up to 12 months
Yes
Johannes Rieger, MD
Principal Investigator
Senckenberg Institute of Neurooncology, University of Frankfurt
Germany: Ethics Commission
ERGO
NCT00575146
December 2007
February 2010
Name | Location |
---|